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Developing new HEALTH
TECHNOLOGIES for WOMEN

DEAR FRIENDS AND COLLEAGUES:
In 2012, IPM saw years of research come together in a significant achievement —
the start of the first efficacy study of a long-acting HIV prevention option for
women, IPM’s monthly dapivirine ring.
From the start, our goal has been to develop products that merge science with
the social, cultural and behavioral complexities that shape the lives of women
who are in urgent need of new health solutions. The Ring Study, along with
additional studies that make up IPM’s Dapivirine Ring Licensure Program, is a
seminal step forward in the development of new, self-initiated HIV prevention
options for women.
With last year’s US FDA approval of the antiretroviral-based drug Truvada for
use as pre-exposure prophylaxis, or PrEP, HIV prevention research has surged
forward. The approval was based on the results of multiple clinical trials showing
that ARVs can substantially reduce the risk of HIV infection when used consistently.

Dr. Zeda F. Rosenberg
Chief Executive Officer

These studies made clear an important lesson: the need for products that are
not only efficacious but also easy to integrate into one’s lifestyle.
IPM also recognizes that making HIV prevention work for women means taking
into account other sexual and reproductive health issues that can threaten a
woman’s well-being, such as unintended pregnancy. That is why IPM is applying its
experience in HIV prevention to the development of new multipurpose prevention
technologies that could address multiple health risks in a single product.
We also continue to partner with pharmaceutical and academic partners to
evaluate cutting-edge ARVs with different mechanisms of action, develop
alternative formulations, and build upon current research with additional new
products like combination microbicides, to potentially increase the breadth of
protection against HIV.
IPM is motivated by the work we accomplished in 2012 and prepared for the
challenges ahead as we lead the Dapivirine Ring Licensure Program while
advancing the important products in our pipeline. It is through the strength of
our many partnerships that this work is not only possible but within our reach.
We extend our deepest gratitude to our global partners for making IPM’s work
possible: governments, foundations, private corporations, community research
groups and advocates — and especially to the individuals who volunteer for
our studies. To our donors around the world, we thank you for your continued
commitment to moving health technologies for women forward, from science
to solutions.

DR. ZEDA F. ROSENBERG

DR. PETER B. CORR

Dr. Peter B. Corr
Chair of the Board

from SCIENCE to SOLUTIONS
IN 2012 IPM moved microbicide development forward with the start of The Ring Study, the first Phase III efficacy
study of a vaginal ring for HIV prevention. Now, two parallel Phase III studies are evaluating the monthly dapivirine ring
across 20 sites in Africa: IPM’s Ring Study and the ASPIRE study, being conducted by our partner the Microbicide Trials Network
(MTN). These sister studies, along with other supporting safety studies, make up the Dapivirine Ring Licensure Program.
Pending results in 2016, this broad package of clinical studies is designed to provide the evidence needed to secure regulatory
approvals and licensure for this potentially new lifesaving tool — an important step toward delivering on IPM’s mission.

The Dapivirine Ring:
Advancing the Promise of Prevention

IPM designed the Dapivirine Ring Licensure Program with two

IPM developed the monthly dapivirine vaginal ring to provide

approval as short as possible. Given the ring’s promise, the MTN,

women with a discreet and easy-to-use tool they could use to

which is funded by the US National Institutes of Health, partnered

protect themselves against HIV infection — the leading cause

with us on this effort. Together, The Ring Study and MTN’s ASPIRE

of death among women of reproductive age worldwide. The

study will evaluate the dapivirine ring among more than 5,000

efficacy studies running concurrently to keep the time line to

women ages 18-45 to determine

long-acting ring slowly releases the antiretroviral (ARV) drug

consistent use and help ensure effectiveness.
The ring’s active ingredient
Dapivirine is a potent non-nucleoside reverse transcriptase
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inhibitor, or NNRTI, which works by preventing HIV from
replicating inside healthy cells. IPM acquired a royalty-free
license to develop dapivirine as a microbicide for use in
developing countries in 2004 through a landmark public-private
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dapivirine over the course of one month. Because women
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whether it helps to prevent
HIV infection and is safe
for long-term use. The
Ring Study is expected
to include 1,650 women
across six sites in South
Africa and Uganda

Supporting
Studies

when fully enrolled.
ASPIRE is expected to
enroll nearly 3,500 women

collaboration with Janssen R&D Ireland.

at more than 15 sites in Malawi,
South Africa, Uganda and Zimbabwe.

The Licensure Program At-a-Glance
The Dapivirine Ring Licensure Program is the culmination of
years of clinical development demonstrating the product’s
safety, long-acting duration, and acceptability to women and
their male partners — and its potential to expand women’s
HIV prevention options with an affordable, self-initiated tool.
Results are expected by 2016.

Supporting studies
IPM is also leading at least seven smaller safety studies needed to
help secure regulatory approval for the ring. Among them is a study
that began in 2012 looking at possible drug interactions, and studies
evaluating ring use with male and female condoms that started in
2013. Studies on the effect of menses and tampon use as well
as extended use of the ring are being planned for 2014. MTN,

Joining forces — Phase III sister studies

in partnership with IPM, is planning two additional studies for

Because at least two Phase III efficacy trials are generally

2014 that will evaluate the dapivirine ring’s safety in adolescents

needed for a product to be eligible for regulatory approval,

and women over 45.
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Promoting Adherence
In a clinical study, product adherence (use of the study
product as directed) is critical to determining whether
the product works — in the case of the dapivirine ring, to
prevent HIV. We know from several earlier HIV prevention
studies that achieving robust product adherence can be a
challenge, but that ARV-based methods can protect against
infection when used consistently. We are taking a number of
steps to measure and encourage adherence in both Phase III
studies of the dapivirine ring.

Laying the Groundwork for Licensure
IPM continues to actively prepare for the dapivirine ring’s potential

licensure so that the product may be distributed quickly at low cost to
women most at risk for HIV. In 2012, IPM worked with regulatory
authorities in Africa to
define country-specific
requirements for rapid
regulatory submission and
marketing approval. IPM
also continues to receive
scientific and regulatory

Assessing Adherence

advice from the US Food and

The Ring Study and ASPIRE will collect
used rings each month to measure the
amount of drug left in the product, which
will tell us whether it was used for all or
just part of the month. The studies also
evaluate drug concentrations in plasma and vaginal fluid
samples, and are using qualitative measures such as interviewer-led questionnaires, diary cards,
focus groups and in-depth interviews
to understand how women are using
the product. Adherence counseling and education is a focus
of regular visits, and community engagement activities
highlight the importance of adherence.

Drug Administration (FDA),

Offering Options
It is hoped that the ring’s monthly duration may help women
use it consistently. As the contraceptive field has taught us,
no single prevention product will be acceptable or appropriate
for everyone. An array of safe and effective HIV prevention
tools will be needed to meet women’s needs and preferences.

the European Medicines
Agency (EMA) and the World
Health Organization (WHO),
to help expedite future
marketing authorization.
This includes EMA review of the ring under Article 58, which will
provide an opinion on the product’s use in developing country settings,
followed by WHO drug prequalification. Both mechanisms are key
steps toward accelerating the ring’s availability in countries with high
rates of HIV where women urgently need new prevention tools.

Partnering on the Path to Access
Successful introduction and rollout of microbicides will require collaboration across sectors, including governments, industry, communities,
NGOs and advocates. IPM is working alongside other HIV prevention
partners to align access activities and develop paths to commercialization that will be customized on a country basis across sub-Saharan
Africa and beyond. As a key element of our access strategy, these
activities leverage partnerships at each point in the value chain —
from marketing and product launch to ongoing pharmacovigilance and
program implementation. Other strategies to enhance access
include efforts to reduce costs to the user in a number
of ways, including potentially extending the ring’s
duration of use for multiple months at a time.
Manufacturing advances
IPM scientists worked with QPharma in Malmö,
Sweden, in 2012 to further optimize the ring
production process for the Phase III trials, which
led to more than a doubling of yields as it
shortened time lines — and will help keep
costs as low as possible at scale-up.
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Forging Public-Private Partnerships to Improve Women’s Health
Since IPM was founded as a nonprofit product developer in 2002, we have leveraged public, philanthropic and private
sector funding and scientific ingenuity to spur development of safe and effective
lifesaving technologies for women. For example, IPM’s partnerships with major
pharmaceutical companies in the HIV prevention effort have led to six non-exclusive,
royalty-free licensing agreements which allow IPM to develop and manufacture eight
different ARV compounds as microbicides or multipurpose prevention technologies
(MPTs) for use by women in developing countries. These agreements ensure that
IPM’s products will be made as affordable and accessible as possible where
they are needed most.
From Promise to Products
In just seven years since IPM acquired dapivirine
from Janssen, we took the monthly ring from
scientific concept to our Dapivirine Ring Licensure
Program now under way. We are also building on our ring
technology with an MPT ring that contains both dapivirine and the contraceptive levonorgestrel
to help reduce the dual risks women face from HIV and unintended pregnancy.

Safety Study Results Are In

Building Capacity

High adherence and acceptability
A microbicide, no matter how effective, will not prevent HIV unless
women find it easy to incorporate into their varying lifestyles. As IPM
reported in 2012, results from a safety study of the dapivirine ring
among 280 HIV-negative women in Kenya, Malawi, South Africa and
Tanzania showed the ring was safe, well-tolerated and used regularly
during the study. Nearly all participants found the ring acceptable
and said they would use it if it is shown to prevent HIV, supporting
previous IPM findings on the ring’s acceptability.

IPM worked closely with the research center partners leading
our trials in Africa to build local capacity through infrastructure
improvements, regular trainings for research staff on clinical and
laboratory compliance, workshops on adherence and counseling,
scientific meetings for center staff, and support for community
engagement and communications outreach. These collaborations
have contributed to more HIV awareness, men’s involvement in
HIV prevention efforts, women’s empowerment through education
and counseling, employment opportunities and professional
development, as well as improved access to health services in
high-risk communities.

Low systemic absorption: The same study showed that only low
levels of dapivirine were detected systemically, which could minimize
potential side effects and reduce the possible risk for drug resistance.
Right drug, right amount, right place: Results of one smaller safety
study released in 2012 showed that, in vaginal fluid samples, dapivirine
reached high concentration levels and remained active against HIV,
further supporting advancement of the dapivirine ring.
Gels are safe and acceptable
Results presented in 2012 from a safety study evaluating two dapivirine
gel formulations among 128 women in the United States showed
both products to be safe and well-tolerated. In addition, dapivirine
was released at high levels and retained anti-HIV activity in vaginal
fluid samples. Two-thirds of participants in the United States said
they would use the gel if it were proven effective against HIV. Also,
a joint IPM and MTN male tolerance study of dapivirine gel showed

IPM in 2012 helped procure
freezers, generators and
temperature monitoring
systems for research
center partners conducting
The Ring Study, which
saved the time and
expense of transporting
samples to a lab for
storage, and expanded
partners’ capacity to
conduct future research
(funded by OFID).

it to be safe, adding to the body of data supporting dapivirine.

from SCIENCE to SOLUTIONS

3

IPM’s CEO Dr. Zeda Rosenberg with NIAID Director Dr. Carl Dieffenbach
(far left), Ring Study Protocol Chair Dr. Saidi Kapiga, MTN Principal
Investigator Dr. Sharon Hillier and ASPIRE Protocol Chair Dr. Jared Baeten
at a joint press briefing on the dapivirine ring at the 2012 International
AIDS Conference in Washington, DC.

Progress in the Pipeline

Confronting dual risks with an MPT Ring

IPM’s leading-edge pipeline responds to women’s urgent need for

Integrated solutions like a long-acting MPT ring could help reduce

tools that can prevent HIV, and address other sexual and reproductive

the high rates of both HIV infection and maternal and newborn

health concerns. Bringing the global HIV epidemic to an end will

deaths associated with unintended pregnancy. In 2012, through a

require a diverse toolkit of products women can fit into their varying

grant from USAID, IPM continued work on a 60-day MPT ring, which

lifestyles and that meet the need for
increasingly effective methods that
will prevent HIV over time. To that

provides sustained release of the ARV dapivirine and the contraceptive
hormone levonorgestrel. Building on our existing dapivirine ring
technology, IPM, in collaboration with our partners Particle Sciences,

end, IPM is developing multiple

Inc. (US) and Queens University Belfast (UK), is evaluating several

ARVs with different mechanisms

lead prototypes of the ring, with clinical studies planned for 2015.

of action in single and combination

IPM researchers are also investigating the potential of the MPT ring

rings, gels, films and tablets. IPM

to be used for up to one year.

is also advancing a multipurpose
prevention technology (MPT) that
could protect women against the
dual risks of HIV and unintended
pregnancy.

Dapivirine-maraviroc ring for added protection
In 2012, IPM and MTN completed a Phase I safety trial of the first
combination microbicide, IPM’s dapivirine-maraviroc ring, as well as
a maraviroc-only ring, with results expected in 2013. Combining the
ARV maraviroc, an entry inhibitor that acts early in the HIV life cycle,
with dapivirine, which acts later in the virus’ life cycle, could broaden
protection against HIV and increase the product’s potency. IPM is
working to further optimize this product, and a second safety study
is planned for 2015.
Other maraviroc products: IPM is also studying maraviroc as
a film, alone and in combination with other ARVs, in partnership
with the Magee Women’s Research Institute at the University of
Pittsburgh, with funding from NIH.
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Partners in Advocacy
DS003 — new mechanism of action
A potent gp120-binder licensed to IPM by Bristol Myers-Squibb,
DS003 (also known as BMS 793) works by binding to a protein on
the surface of HIV to prevent its entry into a healthy cell. Because
the drug targets HIV itself, it has the potential to render the virus
non-infectious when it enters the body with few possible side effects.
Why DS003? DS003 is also an important candidate for development
because its mechanism of action has yet to be used for HIV treatment
or prevention, which means it would be unlikely to interfere with
therapeutic regimens or result in resistance to other ARVs. IPM has
formulated the drug as a vaginal tablet and conducted work in 2012
that supports advancing the compound’s development as a vaginal
ring, either alone or in combination with another ARV.
Partnering on pipeline expansion
IPM supplies other nonprofit product developers with compounds and
regulatory support for several products in the field, including dapivirine
and DS003 vaginal films and maraviroc-based rectal gels, both under
NIH-funded programs, as well as dapivirine-darunavir gel and rings
under the European Commission-funded CHAARM consortium.
Looking ahead
IPM continually surveys emerging data and consults with pharmaceutical
partners to source new compounds. These include novel drugs that
target specific enzymes such as integrase and protease inhibitors,
which may have benefits for HIV prevention.

Awareness-raising is crucial
to building broad political,
public and financial support
for microbicides, and other
tools women need to protect their sexual and reproductive health.
In 2012, IPM worked with a network of civil society partners
across sub-Saharan Africa, Europe and North America — from
local and national NGOs to professional medical societies. With
women’s health and the promise of an AIDS-free generation at
the top of their agendas, these influential advocacy coalitions
partnered with IPM to host stakeholder roundtables, brief
policymakers, and engage communities and media to help ensure
government and public policy support for microbicides and MPTs.

Scientific Contributions
IPM continued to make scientific contributions to the field in
2012 by publishing in peer-reviewed journals and presenting
at major international conferences, including the International
AIDS Conference, the Conference on Retroviruses and Opportunistic
Infections and Microbicides 2012. IPM conducted or supported
studies on dapivirine safety, acceptability and pharmacokinetics,
along with work on combination microbicides and MPTs, all of
which were featured in more than 45 presentations and publications.

IPM co-hosted five sessions at the 2012 International
AIDS Conference in July in Washington, DC, including
this one with Women Deliver called “Advancing the
Integration of Sexual and Reproductive Health.”

2012 Financial Considerations
IPM’s cash, cash equivalents and short-term
investments as of December 31, 2012 were $37.2
million. As a result of the ongoing tightening of
the global economy, IPM continues to adjust its
financial and operating model to ensure the
organization maximizes and efficiently allocates
donor funds to address program needs and carry
out IPM’s mission. These activities have focused
on streamlining personnel and making various
system improvements, including introducing an
Enterprise Resource Planning (ERP) system.
During 2012, IPM increased clinical research
center expenditures in Africa in anticipation and
support of the start of The Ring Study, the first Phase
III clinical trial of the dapivirine ring. Research
center costs included the purchase of laboratory
equipment, and the hiring and training of personnel
to support the trial. In addition, IPM made infrastructure investments across the organization
to ensure accurate and timely reporting of clinical
trial, financial and operating data.
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IPM also continued to advance the product pipeline
in 2012, though at a slower pace than the previous
year due to the limited availability of donor funds
allocated to product development. However, new
funding received in 2013 will allow IPM to expedite
pipeline development in the coming year, an
integral component of the organization’s strategy
beyond our broader Dapivirine Ring Licensure
Program. IPM will continue to apply a highly
disciplined approach to product prioritization that
advances only the most promising self-initiated HIV
prevention tools, and other sexual and reproductive
health technologies for women.
IPM’s Board of Directors, management team and
staff are committed to capably delivering on our
mission for women around the world, and for the
donors whose support fuels our progress. Sustained
funding for IPM’s success is essential, and we
continue to advocate for increased funds from
existing donors and pursue new sources of
support to efficiently achieve our goals.
ASSETS
Cash and cash equivalents
Short-term investments
Accounts receivable
Prepaid expenses and other assets
Property and equipment
Total Assets

DEC. 31, 2012
$7,913,596
$29,356,232
$2,416,907
$1,575,408
$2,219,180
$43,481,324

LIABILITIES AND NET ASSETS
Liabilities
Accounts payable and accrued expenses
Grant advances and deferred revenue
Total Liabilities

$2,740,137
$20,002,490
$23,754,899

Net Assets
Unrestricted
Temporarily restricted
Total Net Assets

$19,726,425
$0
$19,726,425

TOTAL LIABILITIES AND NET ASSETS

$43,481,324

Research center partner
staff with IPM leadership
in Cape Town, South Africa.
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